Shares of Akcea Therapeutics Inc (NASDAQ:AKCA) have been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $30.00.
A number of research firms have weighed in on AKCA. BMO Capital Markets lifted their price target on shares of Akcea Therapeutics from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. BidaskClub downgraded shares of Akcea Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Zacks Investment Research downgraded shares of Akcea Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Finally, Stifel Nicolaus lifted their price target on shares of Akcea Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday.
Several large investors have recently modified their holdings of the company. MetLife Investment Advisors LLC acquired a new stake in shares of Akcea Therapeutics in the 4th quarter valued at $199,000. Iguana Healthcare Management LLC acquired a new stake in shares of Akcea Therapeutics in the 4th quarter valued at $1,736,000. Ardsley Advisory Partners boosted its stake in shares of Akcea Therapeutics by 50.0% in the 4th quarter. Ardsley Advisory Partners now owns 15,000 shares of the company’s stock valued at $260,000 after purchasing an additional 5,000 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Akcea Therapeutics in the 4th quarter valued at $598,000. Finally, Deutsche Bank AG boosted its stake in shares of Akcea Therapeutics by 17.4% in the 4th quarter. Deutsche Bank AG now owns 34,624 shares of the company’s stock valued at $600,000 after purchasing an additional 5,134 shares in the last quarter. Institutional investors own 29.14% of the company’s stock.
Akcea Therapeutics (NASDAQ AKCA) traded up $3.07 on Thursday, reaching $31.21. 1,322,014 shares of the company’s stock were exchanged, compared to its average volume of 497,941. Akcea Therapeutics has a 1 year low of $8.10 and a 1 year high of $32.47.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/03/18/akcea-therapeutics-inc-akca-receives-25-67-average-target-price-from-analysts.html.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.